Despite hype, still much to uncover about immunotherapy – BioPharma Dive
|
Despite hype, still much to uncover about immunotherapy
BioPharma Dive The recent successes of cancer immunotherapy, headlined by the checkpoint inhibitors already earning billions in sales, have spurred heavy investment into the space as biopharmas race to move promising candidates into later-stage development. |
